Vanguard S&P 500 ETF (VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as market trends shift in 2026, many investors are also exploring specialized sectors and ETFs that may offer stronger growth potential than the broader S&P 500 (SPX) index. Using TipRanks’ ETF comparison tool, we identified three of BlackRock’s (BLK) ETFs, namely iShares Biotechnology ETF (IBB), iShares MSCI China ETF (MCHI), and iShares Global Healthcare ETF (IXJ), as high-conviction funds, each offering 20%+ upside for investors in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks’ ETF analyst consensus—based on a weighted average of ratings for each fund’s holdings—IBB offers a huge upside of more than 34%. Meanwhile, MCHI and IXJ offer upside potential of about 25.9% and 21.2%, respectively. All three significantly exceed the roughly 17.6% upside projected for VOO.
Let’s break it down.
iShares Biotechnology ETF (IBB)
The iShares Biotechnology ETF (IBB) provides exposure to U.S. biotechnology companies, ranging from large drugmakers to emerging biotech firms. Its top three holdings are Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN). Overall, IBB holds 246 stocks and manages about $8.03 billion in assets.
IBB has gained an impressive 42.66% over the past year, driven by strong biotech momentum, new FDA approvals, and rising deal activity across the sector. Even after this rally, analysts still see 34.26% upside ahead as biotech stocks continue to recover. The fund has a 0.44% expense ratio and is best suited for investors seeking higher growth potential, though biotech stocks can remain volatile.
iShares MSCI China ETF (MCHI)
The iShares MSCI China ETF (MCHI) invests in large- and mid-sized Chinese companies, giving investors exposure to the world’s second-largest economy. Its top three holdings are Tencent Holdings (TCEHY), Alibaba Group (BABA), and China Construction Bank. Overall, the fund holds 579 stocks and manages about $6.74 billion in assets while tracking the MSCI China Index.
MCHI has gained nearly 10% over the past year as valuations in China have started to recover. Analysts currently see 25.95% upside for the fund as investors look for a broader rebound in Chinese markets. With a 0.59% expense ratio, MCHI offers diversified exposure to major Chinese technology, financial, and consumer companies.
iShares Global Healthcare ETF (IXJ)
The iShares Global Healthcare ETF (IXJ) gives investors exposure to pharmaceutical, biotechnology, and medical device companies from around the world. Its top three holdings are Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). Overall, the fund holds 114 stocks and manages about $3.58 billion in assets.
IXJ has a low 0.40% expense ratio and offers a 1.47% dividend yield. Analysts currently see 21.25% upside for the ETF, making it a balanced option for investors looking for global healthcare exposure with a mix of growth and stability.